Company intelligence / Profile preview

Biogenysis

College Station, Texas, United States

Ownership: Private
Development stage: Other

Overview

Biogenysis has advanced patent applications (US, EPO) for anti-SARS-CoV-2 monoclonal antibodies, and early partnership efforts for AI-driven Alzheimer’s disease biomarker assays, as well as producing fully human monoclonal antibodies for a range of viruses. No marketed products or reported clinical trial results to date

Therapeutic areas: Infectious DiseasesNeurology
Modalities: Monoclonal antibodyProteinDiagnostic (biomarker assay)AI platform for therapeutic discovery
Industry: Biotech

Partnerships

Khalpey AI LabContenta, Ltd. (Estonia)Enzolytics (parent)

Beyond the preview

Go deeper on Biogenysis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogenysis.

Explore the full profile